Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2014
Filed with the SEC on Jul 31, 2014 and accepted by EDGAR at Jul 31, 2014, 21:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-04-01 to 2014-06-30 | $138.4m | us-gaap:Revenues |
| Revenue | 6 months2014-01-01 to 2014-06-30 | $256.9m | us-gaap:Revenues |
| Cost of revenue | 3 months2014-04-01 to 2014-06-30 | $9.7m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2014-01-01 to 2014-06-30 | $18.2m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2014-04-01 to 2014-06-30 | $224.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2014-01-01 to 2014-06-30 | $463.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2014-04-01 to 2014-06-30 | $77.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2014-01-01 to 2014-06-30 | $151.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2014-04-01 to 2014-06-30 | −$180.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2014-01-01 to 2014-06-30 | −$397.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2014-04-01 to 2014-06-30 | $693.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2014-01-01 to 2014-06-30 | $1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-04-01 to 2014-06-30 | −$159.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2014-01-01 to 2014-06-30 | −$391.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-04-01 to 2014-06-30 | −$0.68 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2014-01-01 to 2014-06-30 | −$1.68 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-04-01 to 2014-06-30 | −$0.68 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2014-01-01 to 2014-06-30 | −$1.68 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-04-01 to 2014-06-30 | 233,808,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2014-01-01 to 2014-06-30 | 233,353,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2014-01-01 to 2014-06-30 | −$303.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2014-01-01 to 2014-06-30 | $27.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-06-30 | $420.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-06-30 | $1.35bn | us-gaap:AssetsCurrent |
| Total assets | At period end2014-06-30 | $2.12bn | us-gaap:Assets |
| Current liabilities | At period end2014-06-30 | $363.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-06-30 | $945.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-06-30 | $1.17bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-14-000058. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.